drugset / Trial / NCT03943056

A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants

NCT03943056

Phase 1 Completed 64 enrolled Biogen
RandomizedSequentialQuadruple-blindTreatment

Summary

This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of BIIB091 in healthy participants.This study will also determine the effect of food on the single oral dose pharmacokinetic (PK).

Timeline

Start
2019-05-13
Primary completion
2020-01-10
Completion
2020-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject BIIB091 Small molecule Oral

Indications

No indication recorded.